|
57 Products |
| 57 Products |
|
190 Diseases |  |
11246 News |  |
| «12...9899100101102103104105106107108109110» |
- ||| Zeposia (ozanimod) / BMS
Enrollment closed: RADIANCE: Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients (clinicaltrials.gov) - Jan 16, 2014
P2, N=210, Active, not recruiting, Sponsor: Receptos, Inc.
Recruiting --> Active, not recruiting
- ||| Enrollment closed: Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Jan 16, 2014
P4, N=178, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Trial completion: Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression (clinicaltrials.gov) - Jan 16, 2014
P4, N=54, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant (clinicaltrials.gov) - Jan 13, 2014
P3, N=0, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Ponvory (ponesimod) / J&J
New P1 trial: Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-128800 in Healthy Subjects (clinicaltrials.gov) - Jan 6, 2014
P1, N=16, Completed, Sponsor: Actelion
- ||||| Mayzent (siponimod) / Novartis
New P2 trial: Safety and Efficacy of BAF312 in Dermatomyositis (clinicaltrials.gov) - Jan 5, 2014
P2, N=54, Recruiting, Sponsor: Novartis Pharmaceuticals
- Tysabri (natalizumab) / Biogen, Royalty
Enrollment open: BEST-MS: Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis (clinicaltrials.gov) - Dec 15, 2013
P4, N=600, Recruiting, Sponsor: University Hospital, Toulouse
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- New P2 trial: Efficacy and Safety of FTY720 for Acute Stroke (clinicaltrials.gov) - Dec 3, 2013
P2, N=42, Recruiting, Sponsor: Tianjin Medical University General Hospital
- Enrollment open: Efficacy and Safety of FTY720 for Acute Stroke (clinicaltrials.gov) - Nov 29, 2013
P2, N=42, Recruiting, Sponsor: Tianjin Medical University General Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| ASP4058 / Astellas
New P1 trial: A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP4058 Following Single Oral Doses (clinicaltrials.gov) - Nov 28, 2013
P1, N=130, Completed, Sponsor: Astellas Pharma Global Development, Inc.
- | New P4 trial: Aivojen mikroglia-solujen aktivaation yhteys MS-tautiin (EUDRACT) - Nov 19, 2013
P4, N=60, Ongoing, Sponsor: Turku University Hospital
- ||||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
New P2a trial: Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) - Nov 17, 2013
P2a, N=140, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- ||||| Enrollment closed: Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Nov 10, 2013
P3, N=161, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Extavia (IFN-?-1b) / Novartis
Enrollment change: EPOC: A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Nov 9, 2013
P4, N=1053, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting N=1473 --> 1053
- | Tysabri (natalizumab) / Biogen, Royalty
New P4 trial: BEST-MS: Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis (clinicaltrials.gov) - Nov 7, 2013
P4, N=600, Recruiting, Sponsor: University Hospital, Toulouse
- Mayzent (siponimod) / Novartis
Enrollment open: Pharmacokinetics of BAF312 in Patients With Hepatic Impairment (clinicaltrials.gov) - Oct 27, 2013
P1, N=48, Recruiting, Sponsor: Novartis Pharmaceuticals
N=1473 --> 1053 Not yet recruiting --> Recruiting
- Mayzent (siponimod) / Novartis
Enrollment open: A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function (clinicaltrials.gov) - Sep 23, 2013
P1, N=48, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- mocravimod (KRP-203) / Priothera
Enrollment open: A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies (clinicaltrials.gov) - Sep 18, 2013
P1, N=10, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Enrollment open: Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON) (clinicaltrials.gov) - Sep 17, 2013
P2, N=126, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- fingolimod / Generic mfg.
Trial initiation date: Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod (clinicaltrials.gov) - Sep 10, 2013
P=N/A, N=40, Recruiting, Sponsor: Charite University, Berlin, Germany
Not yet recruiting --> Recruiting Initiation date: Apr 2013 --> Sep 2013
- New P3 trial: Safety and Efficacy of Fingolimod in MS Patients in China (clinicaltrials.gov) - Sep 10, 2013
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
- fingolimod / Generic mfg.
Enrollment open: Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod (clinicaltrials.gov) - Sep 10, 2013
P=N/A, N=40, Recruiting, Sponsor: Charite University, Berlin, Germany
Initiation date: Apr 2013 --> Sep 2013 Not yet recruiting --> Recruiting
- Trial withdrawal: ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon (clinicaltrials.gov) - Aug 26, 2013
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- Enrollment change: ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon (clinicaltrials.gov) - Aug 26, 2013
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Withdrawn N=200 --> 0
- ||| Enrollment change: Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression (clinicaltrials.gov) - Aug 26, 2013
P4, N=54, Completed, Sponsor: Novartis Pharmaceuticals
N=200 --> 0 N=500 --> 54
- |||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Enrollment open: Extension Study of MT-1303 (clinicaltrials.gov) - Aug 26, 2013
P2, N=400, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
N=500 --> 54 Not yet recruiting --> Recruiting
- Trial initiation date: Gilenya in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Aug 15, 2013
P2a, N=30, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Initiation date: May 2013 --> Aug 2013
- Enrollment open: Gilenya in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Aug 15, 2013
P2a, N=30, Recruiting, Sponsor: Massachusetts General Hospital
Initiation date: May 2013 --> Aug 2013 Not yet recruiting --> Recruiting
- ||| Enrollment change: Fingolimod -Response According to Coping - Evaluation (clinicaltrials.gov) - Aug 8, 2013
P4, N=189, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=250 --> 189
- |||| Trial completion: Fingolimod -Response According to Coping - Evaluation (clinicaltrials.gov) - Aug 8, 2013
P4, N=189, Completed, Sponsor: Novartis Pharmaceuticals
N=250 --> 189 Recruiting --> Completed
- | fingolimod / Generic mfg.
Trial initiation date: MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study) (clinicaltrials.gov) - Aug 4, 2013
P2/3, N=88, Recruiting, Sponsor: Charite University, Berlin, Germany
Recruiting --> Completed Initiation date: Mar 2013 --> Jul 2013
- ||| Extavia (IFN-?-1b) / Novartis
Enrollment change: EPOC: Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change (clinicaltrials.gov) - Jul 24, 2013
P4, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Mar 2013 --> Jul 2013 N=264 --> 200
- | Mayzent (siponimod) / Novartis
New P1 trial: A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function (clinicaltrials.gov) - Jul 18, 2013
P1, N=48, Recruiting, Sponsor: Novartis Pharmaceuticals
- || fingolimod / Generic mfg.
New P3 trial: PARADIGMS: Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis (clinicaltrials.gov) - Jul 2, 2013
P3, N=190, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
New P2 trial: Extension Study of MT-1303 (clinicaltrials.gov) - Jun 30, 2013
P2, N=400, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- |||| Trial completion: An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis (clinicaltrials.gov) - Jun 25, 2013
P2, N=143, Completed, Sponsor: Novartis
N=264 --> 200 Enrolling by invitation --> Completed
- ||||| Mayzent (siponimod) / Novartis
Trial initiation date: Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) (clinicaltrials.gov) - Jun 19, 2013
P3, N=1530, Recruiting, Sponsor: Novartis Pharmaceuticals
Enrolling by invitation --> Completed Initiation date: Jan 2012 --> Dec 2012
- Mayzent (siponimod) / Novartis
Trial termination: Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis (clinicaltrials.gov) - Jun 13, 2013
P2, N=29, Terminated, Sponsor: Novartis Pharmaceuticals
Initiation date: Jan 2012 --> Dec 2012 Completed --> Terminated; Trial was prematurely terminated due to enrollment challenges.
- | fingolimod / Generic mfg.
Enrollment open: MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study) (clinicaltrials.gov) - May 13, 2013
P2/3, N=88, Recruiting, Sponsor: Charite University, Berlin, Germany
Completed --> Terminated; Trial was prematurely terminated due to enrollment challenges. Not yet recruiting --> Recruiting
- | Mayzent (siponimod) / Novartis
Enrollment open: Efficacy and Tolerability of BAF312 in Patients With Polymyositis (clinicaltrials.gov) - May 9, 2013
P2, N=30, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial withdrawal: Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS (clinicaltrials.gov) - May 2, 2013
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- Trial initiation date: Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS (clinicaltrials.gov) - May 2, 2013
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Withdrawn Initiation date: Oct 2012 --> Jul 2013
- Enrollment change: Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS (clinicaltrials.gov) - May 2, 2013
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Initiation date: Oct 2012 --> Jul 2013 N=300 --> 0
- | Enrollment open: Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. (clinicaltrials.gov) - Apr 27, 2013
P3, N=156, Recruiting, Sponsor: Novartis Pharmaceuticals
N=300 --> 0 Ongoing --> Recruiting
- iSONEP (sonepcizumab) / Pfizer, Apollo Endosurgery
Trial termination: iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV) (clinicaltrials.gov) - Apr 21, 2013
P1, N=12, Terminated, Sponsor: Lpath, Inc.
Ongoing --> Recruiting Active, not recruiting --> Terminated; Sponsor decision; not safety related
- iSONEP (sonepcizumab) / Pfizer, Apollo Endosurgery
Enrollment change: iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV) (clinicaltrials.gov) - Apr 21, 2013
P1, N=12, Terminated, Sponsor: Lpath, Inc.
Active, not recruiting --> Terminated; Sponsor decision; not safety related N=32 --> 12
- mocravimod (KRP-203) / Priothera
Trial termination: Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus (clinicaltrials.gov) - Apr 10, 2013
P2, N=22, Terminated, Sponsor: Novartis Pharmaceuticals
N=32 --> 12 Recruiting --> Terminated
- mocravimod (KRP-203) / Priothera
New P1 trial: A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies (clinicaltrials.gov) - Apr 9, 2013
P1, N=10, Recruiting, Sponsor: Novartis Pharmaceuticals
- mocravimod (KRP-203) / Priothera
Trial termination: Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients (clinicaltrials.gov) - Mar 20, 2013
P2, N=35, Terminated, Sponsor: Novartis Pharmaceuticals
Recruiting --> Terminated Completed --> Terminated
- fingolimod / Generic mfg.
Biomarker: MS-BMD: A Pilot Study Assessing the Impact of Gilenya Therapy on Bone Density Change in Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Mar 12, 2013
P=N/A, N=44, Recruiting, Sponsor: Simnad, Virginia, M.D.